Condensed Consolidated Balance Sheets - USD ($)	Jun. 30, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 52,067,339	$ 35,300,805
Receivable due from collaboration agreement	489,221
Research and development tax incentive receivable	932,057
Prepaid assets and other current assets	1,968,726	2,258,229
Total current assets	55,457,343	37,559,034
Property and equipment, net	1,697,038	1,102,808
Total assets	57,154,381	38,661,842
Current liabilities:
Accounts payable	1,509,224	1,297,725
Deferred research grant revenue	25,000	24,315
Total liabilities	1,534,224	1,322,040
Commitments and contingencies (see Note 4)
Stockholders’ equity:
Common stock; $0.001 par value, 45,000,000 shares authorized; 25,371,781 and 22,534,874 shares issued and outstanding as of June 30, 2021 and December 31, 2020, respectively	25,372	22,535
Additional paid-in capital	102,301,550	71,648,453
Accumulated other comprehensive loss	(116,830)	(51,538)
Accumulated deficit	(46,589,935)	(34,279,648)
Total stockholders’ equity	55,620,157	37,339,802
Total liabilities and stockholders’ equity	$ 57,154,381	$ 38,661,842